DiaMedica begins Phase II trial to treat acute ischemic stroke
US-based biopharmaceutical firm DiaMedica Therapeutics has begun a Phase II clinical trial (REMEDY) of its therapeutic candidate DM199 for the treatment of patients with acute ischemic stroke. (Source: Drug Development Technology)
Source: Drug Development Technology - September 12, 2017 Category: Pharmaceuticals Source Type: news
Eisai reports positive data from Phase Ib/II study of lenvatinib for RCC
Eisai has reported positive interim results from a Phase Ib/II clinical trial (Study 111) of Kisplyx (lenvatinib) in combination with Merck ’s anti-PD-1 therapy pembrolizumab (Keytruda) to treat patients with advanced renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news
Realm Therapeutics to initiate Phase II trial for allergic conjunctivitis
Realm Therapeutics is set to initiate a Phase II clinical trial of PR013 to treat allergic conjunctivitis (AC), following approval of its investigational new drug (IND) application by the US Food and Drug Administration (FDA). (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news
Researchers report positive results from two melanoma trials in Australia
Researchers at Melanoma Institute Australia have reported positive results from two clinical trials, COMBI-AD and CheckMate 238, conducted to stop and prevent melanoma progression. (Source: Drug Development Technology)
Source: Drug Development Technology - September 11, 2017 Category: Pharmaceuticals Source Type: news
Eisai and Ono Pharma to conduct Phase Ib combination trial for liver cancer
Eisai and Ono Pharmaceutical are planning to conduct a Phase Ib clinical trial of Lenvima (lenvatinib mesylate) in combination with Opdivo (nivolumab), as part of their collaboration agreement to jointly develop the therapy for hepatocellular carcino … (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news
Leap Therapeutics and EORTC to initiate combination trial of oncology drugs
US-based biotechnology firm Leap Therapeutics has entered an immunotherapy collaboration with Belgian European Organisation for the Research and Treatment of Cancer (EORTC) to conduct a clinical trial of DKN-01 to treat advanced biliary tract cancers … (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news
Boehringer launches Phase IIa trial for diabetic retinopathy
Boehringer Ingelheim has launched a Phase IIa clinical trial (ROBIN) of its product candidate BI 1467335 to treat patients with non-proliferative diabetic retinopathy (NPDR). (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2017 Category: Pharmaceuticals Source Type: news
Caris ’ studies show use of molecular profiling to develop oncology therapies
US-based Caris Life Sciences has reported positive data from two studies conducted for the validation of its tumour molecular profiling approach to guide the development of therapeutic strategies. (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies
KamRAB/KedRAB ™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma. (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
Deals this week: Sanofi, Entasis Therapeutics, Helsinn Therapeutics (US)
Sanofi has entered a research agreement with drug discovery services provider Axxam. (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
August ’s top stories: Cancer Research UK’s new oncology trial, Novartis’ malaria drug trial
Cancer Research UK initiated a trial of LY3143921 hydrate to treat patients with advanced solid tumours, and Novartis and MMV initiated a Phase IIb trial of KAF156 to treat multidrug-resistant malaria in Africa. Drugdevelopment-technology.com wraps u … (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news
Amgen and AstraZeneca report positive results of Phase IIb asthma trial
Amgen and AstraZeneca have reported positive results from a Phase IIb clinical trial (PATHWAY) of tezepelumab to treat patients with severe uncontrolled asthma. (Source: Drug Development Technology)
Source: Drug Development Technology - September 6, 2017 Category: Pharmaceuticals Source Type: news
Aelix commences enrolment in Phase I trial for HIV vaccine
Spanish biotechnology firm Aelix Therapeutics has commenced patient enrolment in a Phase I clinical trial (AELIX-002) of HTI vaccine to treat patients infected with HIV. (Source: Drug Development Technology)
Source: Drug Development Technology - September 6, 2017 Category: Pharmaceuticals Source Type: news
